Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

myeloid cell leukemia 1 inhibitor PRT1419

An orally bioavailable inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1; induced myeloid leukemia cell differentiation protein; myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential antineoplastic activity. Upon oral administration, the MCL1 inhibitor PRT1419 targets and binds to MCL1. This prevents the binding of MCL1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing MCL1. MCL1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	MCL1 inhibitor PRT1419
Code name:	PRT 1419 PRT-1419

myeloid cell leukemia 1 inhibitor PRT1419

Search NCI's Drug Dictionary